Search

Displaying results 2051 - 2060 of 4590 in total
  1. Drug

    Milademetan

    go.drugbank.com/drugs/DB15257
    Investigational

    Milademetan is under investigation in clinical trial NCT02319369 (Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk

  2. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world.

  3. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    [A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.[L1118] It was never approved by the FDA.

  4. Drug

    Lansoprazole

    go.drugbank.com/drugs/DB00448
    ApprovedInvestigational

    along with other pathologies caused by excessive acid secretion. … [A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD)

  5. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] Rusfertide is administered by subcutaneous injection and titrated to maintain hematocrit below 45%.

  6. Drug

    Prussian blue

    go.drugbank.com/drugs/DB06783
    Approved

    It is insoluble in water but also tends to form a colloid thus can exist in either colloidal or water-soluble form, and an insoluble form.

  7. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    [A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased

  8. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur ...

  9. Drug

    Tretinoin

    go.drugbank.com/drugs/DB00755
    ApprovedInvestigationalNutraceutical

    Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is norm...

  10. Drug

    Sulconazole

    go.drugbank.com/drugs/DB06820
    Approved

    Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic derma...